Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EADO 2018 /
The changing landscape of melanoma treatment

6th - 9th Nov 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.11.18
Views: 739
Rating:

Dr Eva Muñoz-Couselo - University Hospital Vall d'Hebron

Dr Eva Muñoz-Couselo speaks with ecancer at the EADO 2018 congress in Barcelona about the changing landscape of melanoma treatment.

Dr Muñoz-Couselo discusses target agents such as the BRAF inhibitor and that the agent must be combined with a MEK inhibitor.

She believes that combination treatments are the future but that superior biomarkers are needed to better determine which treatment is best for patients.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation